Full-Time

Clinical Specialist

Cardiopulmonary

Posted on 10/7/2025

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$145k - $160k/yr

+ Bonus

Remote in USA

Remote

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Customer Service
Excel/Numbers/Sheets
Requirements
  • Perfusion education, current or history of Certified Clinical Perfusionist Certification or Licensure is required with a minimum of 5 years of clinical practice.
  • Ability and desire to teach
  • Works well within teams both cross-functionally and teams that may or may be not located within a specific building or geography
  • Project management skills
  • Excellent written and oral communication skills required
  • Self-confidence and effectiveness in dealing with a wide variety of customer types.
  • Highly effective at working both independently and part of the large-scale collaborative team.
  • Possesses a high energy level and a high degree of interpersonal skills, both verbal and written.
  • Proficiency in computer skills to execute virtual programs and presentations with the customer
  • Desire and ability to participate and motivate others in team efforts.
  • Proficiency in computer applications including Microsoft Word, Excel, PowerPoint, Teams/Zoom.
  • Sit 80% Stand/Walk 20%
  • Repetitive use on computer
  • Lifts 0-50 lbs
  • Ability to understand scientific facts and package them into a cohesive communication model for healthcare professionals
  • Oral and written comprehension
  • Ability to meet hospital credentialing requirements
  • Availability to work weekends when needed
  • Travel within US and abroad
  • Blood Borne Pathogen Exposure
Responsibilities
  • Provides clinical and product education to Healthcare Professionals on the full portfolio of LivaNova Cardiopulmonary products.
  • Training sessions may be conducted in person or virtually and must align with all approved instructions for use.
  • These sessions include coordinating hospital clinical and non-clinical demonstrations, in-person and virtual education programs, intra-operative case coverage, supporting product evaluations and ad hoc training when needed.
  • The clinical specialist must both work independently within their role but remain highly collaborative with their team and company stakeholders (sales).
  • Provides clinicians and medical staff clear clinical instructions to ensure continuity of education and support related to all aspects of patient outcomes, in accordance with the product’s Instructions for Use (IFU).
  • Coordinates, directs, and delivers clinical training programs on LivaNova products, as necessary and appropriate.
  • Develops and maintains product knowledge excellence of the LivaNova CP portfolio of products.
  • Professionally integrates into all accounts building trust and relationships and establishes strong rapport with customers.
  • Collaborates weekly with key internal stakeholders for installations and evaluations, including the Clinical Specialist team, Field/Technical Service & Account Executives – working seamlessly in order to increase all team’s efficiency and time with the customer.
  • Maintains a positive, proactive, customer service manner with customers and sales personnel during stressful situations.
  • Will foster high trust relationships with customers, and all LivaNova team members.
  • Takes a positive, proactive approach to solving complex and/or unusual clinical/therapy/technical problems.
  • Foresees obstacles and plans accordingly for seamless execution.
  • Assists Account Executives in urgent clinical needs and related product information.
  • Responsible for adhering to all regulatory and LivaNova policies to ensure patient safety and company responsibility.
  • Develops and maintain an in-depth knowledge of assigned accounts and customers to include competitor activity.
  • Supports evaluations as needed within and account and supports sales strategies for capital equipment opportunities within accounts.
  • Provides feedback to providers both within operating room setting and outside operating room setting on the directions for use specific to the product and its maintenance.
  • Attend trade shows/conferences/congresses to maintain clinical expertise and current market state, as well as meet customer and support product discussions.
  • Meet all requirements and maintain credentialing status in order to access accounts.
  • Provides sales support when needed on clinical in-services, training and guidance to current or potential customers.
  • Maintains positive and cooperative communications and collaboration with all levels of employees, customers, contractors, and vendors.
  • Performs other related duties and responsibilities, on occasion, as assigned.
  • Collaborates with regional and global marketing teams as needed on ongoing projects, clinical discussion, program development and product development.
  • Contributes to the development of all education programs both internally and externally.
  • Support training of the sales team for new hires, ongoing education and product launches.
  • Team player with a strong ability to collaborate amongst the clinical team as well as other teams within LivaNova (sales, technical service, marketing, quality etc).

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Next-generation aura6000 with MRI compatibility and 15-year battery launches 2026.
  • Medicare coverage application for VNS treatment-resistant depression supported by five peer-reviewed studies.
  • Debt reduction to $377M enables M&A and R&D investment for innovation.

What critics are saying

  • Third-party component supply constraints limit Essenz production despite capacity expansion plans.
  • $400 million litigation payment Q3 2026 reduces cash reserves by approximately 50%.
  • Cardiopulmonary 18.3% Q1 2026 growth unsustainable; normalization triggers analyst downgrades.

What makes LivaNova unique

  • Essenz heart-lung machine revenue exceeded 20% growth in Q3 2025 with China expansion.
  • aura6000 OSA device FDA approval positions LivaNova in underserved $2B+ market segment.
  • VNS therapy epilepsy reimbursement increased 48% January 2026, expanding addressable patient population.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Mar 19th, 2026
LivaNova's aura6000 system gains FDA approval for moderate to severe obstructive sleep apnea treatment

LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.

Yahoo Finance
Feb 25th, 2026
LivaNova reports Q4 2025 results with fifth consecutive year of double-digit EPS growth

LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.

Yahoo Finance
Feb 25th, 2026
LivaNova posts third consecutive year of double-digit growth, targets 80% Essence heart-lung machine placements by 2026

LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.

PR Newswire
Feb 20th, 2026
Orrum partners with LivaNova to integrate CŌRE Insights analytics with Essenz Perfusion System

Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.

BioSpace
May 1st, 2024
Livanova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73

INACTIVE